Condition: Oral Pre-exposure Prophylaxis (PrEP) · Long-acting Injectable Cabotegravir for PrEP · Sponsor: Georgetown University
The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups.
This description comes directly from the study's public registry record.
Charles Holmes, MD, MPH · +1 (202) 662-9000 · charles.holmes@georgetown.edu
Deborah Hoege, MPH · +1 (202) 662-9000 · dh1107@georgetown.edu
Always discuss trial participation with your own doctor first.
| Community Health Science Unit | Lilongwe, Malawi | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07221747